A proven track record of value creation
We are a multinational pharmaceutical company with a local presence across North America and Canada, MENA and Europe, providing our customers with a broad range of generic, specialty and branded pharmaceutical products
Full year 2025 results
Khalid Nabilsi, Deputy CEO, North America and Europe
Our purpose is to put better health within reach, every day
Sustainability reporting
We are dedicated to ensuring patients across the US, Canada, Europe, and the MENA region have access to high-quality medicines. Our mission is to advance health and wellbeing by empowering our people, protecting the environment, and operating with transparency and ethically.
Annual Report
Ensuring patients have access to the medicines they need is at the heart of everything we do. In 2025, we continued to invest in our people, capabilities, and infrastructure to strengthen our ability to deliver high-quality, affordable medicines across the communities we serve.
Latest news
Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes
- Hikma launches Diazepam Injection, USP in the US Press Release, Product 08 July 2026 Hikma launches Diazepam Injection, USP in the US
- Hikma launches XCOPRI® (Cenobamate tablets) in the UAE Press Release, Product 06 July 2026 Hikma launches XCOPRI® (Cenobamate tablets) in the UAE
- Hikma welcomes FDA approval of Guardant360® Liquid CDx Press Release, Product 22 June 2026 Hikma welcomes FDA approval of Guardant360® Liquid CDx
- Hikma comments on Supreme Court of the United States’ unanimous decision in favour of Hikma Press Release, Corporate 04 June 2026 Hikma comments on Supreme Court of the United States’ unanimous decision in favour of Hikma